Tarextumab: Additional Phase Ib data

Data from 31 patients with previously untreated metastatic pancreatic cancer in the Phase Ib portion of the double-blind, U.S. Phase Ib/II ALPINE trial showed that 2.5-15 mg/kg IV tarextumab every other week plus gemcitabine and Abraxane nab-paclitaxel led to a median PFS of 5.6 months and a median OS of 11.6 months. In patients whose tumor samples had elevated levels of NOTCH3 gene expression, median PFS was 6.6 months and median OS was 14.6 months. In 29 patients evaluable for a RECIST response, there were 11 partial responses and 10 cases of stable disease. Data were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco. ...